MY ACCOUNT | NEWSLETTER |

KARL STORZ Acquires Medical Business of Visual Collaboration Software Company T1V


The family-owned MedTech company KARL STORZ is pleased to announce the acquisition of the medical business of T1V, a US-based visual collaboration software company. KARL STORZ has had a longstanding partnership with T1V to build its existing CollaboratOR portfolio. This acquisition marks a significant step for KARL STORZ in shaping integrated hardware and software solutions for digital surgery in global operating rooms, complementing its state-of-the-art endoscopes and high-end medical solutions. The CollaboratOR has been sold exclusively through KARL STORZ since 2018.

T1V drives technological solutions in the operating room

Based in Charlotte, North Carolina, T1V is a leading innovator in large-scale, interactive technology. The CollaboratOR portfolio offers a sophisticated hardware and software cloud ecosystem accessed through a large-format touch display. This system provides surgical staff with real-time clinical data, pre-operative and real-time images, preference cards, and other critical data throughout the peri-operative process. The cloud ecosystem is integral to enabling real-time collaboration during surgery and is designed to significantly improve workflow for major healthcare enterprises. KARL STORZ’s extensive customer base, including healthcare enterprises worldwide, will benefit from the integration into the company of T1V’s digital competencies and intellectual property, which includes all its patents in visual collaboration software. This will enhance capabilities in multi-touch data interaction, cloud-based collaboration, low-latency streaming, multi-view windowing, and remote support. The CollaboratOR is a crucial part of KARL STORZ's digital ecosystem offering, which will continue to grow.

Commitment to meet the future needs of healthcare partners

“This strategic acquisition underscores our commitment to preparing for future opportunities to advance progress in digital surgery and shape the future of medicine,” said Stefan Ort, KARL STORZ’s Chief Operating Officer. “It ensures the future development of our CollaboratOR range, which enhances our ability to empower healthcare partners to excel daily, improving patients' lives globally.” The acquired T1V medical business will be fully integrated into KARL STORZ over the next 12 months, including all operations, research and development activities, sales support, and technical services. As part of the acquisition, a team of ten T1V employees relevant to the medical business will transition to KARL STORZ. Christy Gaudet, KARL STORZ’s Vice President Sales & Marketing Surgical & OR1 in the US, added: “Hundreds of successful CollaboratOR installations exemplify our dedication to innovation and digitalization. We are proud to offer a unique, best-in-class integration solution, highlighted by CollaboratOR and strengthened by this acquisition.”

About KARL STORZ

The medical technology company KARL STORZ was founded in 1945 in Tuttlingen, Germany, and is an international leader in the world of endoscopy. Now in its third generation, the family-owned company employs 9,400 people in more than 40 countries worldwide. The company portfolio includes 13,000 products for human and veterinary medicine. KARL STORZ stands for visionary design, precision craftsmanship and clinical effectiveness. Production sites are located in Germany, the USA, Switzerland and Estonia.


Source: www.karlstorz.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Saint Roch Veterinary LLC, Announces Breakthrough in Canine Dental Health With Revolutionary Periodontal Disease Treatment

Like0
Dislike0

Wedgewood Appoints Stanley Howell as Chief Operations Officer to Drive Growth and Operational Excellence

Like0
Dislike0

Identification and genomic characterization of feline calicivirus from a leopard cat (Prionailurus bengalensis) in Taiwan.

Like0
Dislike0

Treatment success in cats with chronic enteropathy is associated with a decrease in fecal calprotectin concentrations

Like0
Dislike0

Myocardial injury in dogs: a retrospective analysis on etiological, echocardiographic, electrocardiographic, therapeutic, and outcome findings in 102 cases

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top